Skip to main content
. 2020 Oct 7;9(10):e1189. doi: 10.1002/cti2.1189

Figure 1.

Figure 1

Validation of SARS‐CoV‐2 RBD‐S and spike antigens in COVID‐19 samples. Reducing SDS‐PAGE analysis of (a) RBD‐S and (b) trimeric spike purified from transiently transfected mammalian HEK293 cells. (c) Binding of CR3022 IgG1 mAb to SARS‐CoV‐2 RBD‐S and (d) trimerised spike. The anti‐dengue virus 1M7 IgG1 mAb 42 was used as a control. (e) Detection of serum IgG from a COVID‐19 patient (left), but not from pre‐2020 serum (centre) or no serum control (right). (f) Detection of IgM and IgG to RBD‐S in serial time the course serum samples from a COVID‐19 patient and not in pre‐COVID‐19 pandemic healthy volunteer sera (HV1,HV2). All sera diluted 1:50, and for the COVID‐19 patient (CD×‐881.0001), day after symptoms onset is shown on the x‐axis. (g) Anti‐spike IgG reactivity by ELISA for pre‐COVID‐19 pandemic sera (n = 6), the anti‐SARS‐CoV‐1/2 mAb CR3022, and COVID‐19 samples of varying titres (indicated in parentheses).